Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/104692ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
WO 27.05.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/130409 Applicant BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. Inventor XIA, Bing
An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.
2.WO/2022/106057TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES
WO 27.05.2022
Int.Class A61K 8/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
Appl.No PCT/EP2021/025445 Applicant THE BOOTS COMPANY PLC Inventor BELL, Michael, David
According to the present invention there is provided a tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-QTAV-Z wherein Q is used to denote amino acid Glutamine, T is used to denote amino acid Threonine, A is used to denote amino acid Alanine and V is used to denote amino acid Valine, at the N- terminal end, U is independently selected from the group consisting of octanoyl (C8), decanoyl (C10), lauroyl (C12), myristoyl (C14), palmitoyl (C16), stearoyl (C18), biotinoyl, elaidoyl, oleoyle, lipoyle, at the C-terminal end, Z is selected from the group consisting of OH, O R1, NHR1 or NR1 R2, R1 and R2 are independently selected from the group consisting of alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclical, polycyclic, unsaturated, hydroxylates, carbonylated, phosphorylated and/or sulphurous, said groups comprising from 1 to 24 carbon atoms and being capable of including one or more heteroatoms O, S and/or N.
3.WO/2022/105922SSX2 ANTIGEN DERIVED SHORT PEPTIDES
WO 27.05.2022
Int.Class C07K 7/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/CN2021/132192 Applicant XLIFESC, LTD. Inventor LI, Yi
The present invention relates to SSX2 antigen derived short peptides, and in particular to SSX2 derived tumor antigen short peptides, complexes formed by the short peptides and MHC molecules, and uses of the short peptides and complexes. In addition, the present invention also relates to molecules bound to the short peptides or complexes described above, and uses of the molecules.
4.WO/2022/107167BICYCLIC HETEROCYCLIC COMPOUNDS FOR TREATMENT OF TUBERCULOSIS
WO 27.05.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/IN2021/051081 Applicant DR REDDY'S INSTITUTE OF LIFE SCIENCES Inventor REDDY, Gangireddy Sujeevan
The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein ring A, R1, m and n are same as defined in the specification. The present invention also relates to compositions comprising such compounds, use of such compounds and methods of treating a condition, disease or disorder using such compounds and/or compositions.
5.WO/2022/107737SARS-CoV-2 DETECTION KIT AND SARS-CoV-2 DETECTION METHOD
WO 27.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/JP2021/041983 Applicant FUJIFILM CORPORATION Inventor UJIHARA Dai
The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.
6.WO/2022/107812PURIFICATION DEVICE
WO 27.05.2022
Int.Class B01D 9/02
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
DSEPARATION
9Crystallisation
02from solutions
Appl.No PCT/JP2021/042245 Applicant NIPPON SHOKUBAI CO., LTD. Inventor ARAI, Shogo
The present invention relates to a compound purification device having a crystallizer in which N crystallization tanks are connected in series, and a cleaning column for forcibly transporting crystals, wherein the cleaning column has a line for delivering products and a line for returning a mother liquid to an N-th crystallization tank, and the crystallizer has: a line for supplying slurry from the N-th crystallization tank to the cleaning column; a line for feeding slurry from a downstream crystallization tank to an one upstream crystallization tank via a solid-liquid separator; a line for returning, to the original crystallization tank, the mother liquid in which the crystal has been removed in the solid-liquid separator; and a line including, as a line for feeding the mother liquid from the upstream crystallization tank to each of the first to N-1th crystallization tanks, at least one among a line for directly feeding the mother liquid from one upstream crystallization tank and a line for feeding the mother liquid from one upstream crystallization tank via the solid-liquid separator, and further has a line for feeding the mother liquid to the outside of the purification device. The present invention can obtain a compound with high purity and at high yield and low cost.
7.WO/2022/105772BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2021/131080 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
Provided are a bispecific antibody having a neutralizing activity against a coronavirus, and a use thereof. A neutralizing antibody which is against a coronavirus S protein and blocks the binding of the coronavirus S proteins to an ACE 2 receptor is provided to prevent and treat coronaviruses. Specifically provided is an antibody or polypeptide complex specifically binding to a coronavirus S protein, comprising: (a) a first epitope binding moiety comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH and VL form an antigen binding domain specifically binding to a first epitope of an S protein; and (b) a second epitope binding moiety comprising a single-domain antibody or a VHH fragment thereof specifically binding to a second epitope of the S protein, wherein the first and second epitope binding portions are fused to each other and are not identical to each other. Also provided is a polynucleotide for encoding an antibody or a polypeptide complex and a host cell comprising same, and a method for preparing an antibody or a polypeptide complex. The antibody or polypeptide complex can be used for preventing, treating, diagnosing, and/or detecting coronaviruses.
8.WO/2022/105787LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47
WO 27.05.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/131181 Applicant SHENZHEN ENDURING BIOTECH, LTD. Inventor WEN, Yu
Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.
9.WO/2022/105817BI-FUNCTIONAL MOLECULES
WO 27.05.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2021/131389 Applicant SUZHOU TRANSCENTA THERAPEUTICS CO., LTD. Inventor QIAN, Xueming
Provided are proteins comprising a PD- L1-binding moiety linked to a TGFβ-binding moiety, IL-1-binding moiety, immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4) or CD47-binding moiety, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.
10.WO/2022/105832ANTI-PD-L1 NANOBODY AND TRIFUNCTIONAL FUSION PROTEIN
WO 27.05.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/131479 Applicant QURE BIOTECHNOLOGY (SHANGHAI) CO., LTD. Inventor QU, Xiangdong
The present invention relates to an anti-PD-L1 nanobody and a trifunctional fusion protein. The anti-PD-L1 nanobody and an Fc fusion protein thereof are strong in specificity, high in affinity, and weak in immunogenicity in humans, and has a remarkable anti-tumor effect. The trifunctional fusion protein comprises a TGF-β inhibitor, a VEGF inhibitor and a PD-L1 inhibiting antibody, and has a very high affinity for both a human VEGF protein and a TGF-β protein and also a good affinity for a human PD-L1 protein; moreover, the trifunctional fusion protein can also block the binding of the human PD-1/PD-L1 protein.